Enterprise Value

0.00

Cash

52.2M

Avg Qtr Burn

N/A

Short % of Float

0.96%

Insider Ownership

0.05%

Institutional Own.

29.16%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CYAD-231 (NKG2DL) Details
Solid tumor/s, Cancer

Failed

Discontinued

CYAD-221 (CD19) Details
B-cell malignancies, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued

CYAD-02 (NKG2DL) Details
Myelodysplastic syndrome, Blood cancer, Acute myeloid leukemia, Cancer

Failed

Discontinued

CYAD-01 Details
Myelodysplastic syndrome, Blood cancer, Cancer, Acute myeloid leukemia, Multiple myeloma

Failed

Discontinued

CYAD-101 Details
Metastatic colorectal cancer, Cancer

Failed

Discontinued

CYAD-211 (BCMA) Details
Multiple myeloma, Cancer

Failed

Discontinued

CYAD-103 (NKG2DL) Details
Solid tumor/s, Cancer

Failed

Discontinued